ea0029p818 | Endocrine tumours and neoplasia | ICEECE2012
Stigliano A.
, Cerquetti L.
, Sampaoli C.
, Bucci B.
, Amendola D.
, Rosato M.
, Marchese R.
, Novelli G.
, Toscano V.
Background: Actually mitotane is an adrenal-specific agent employed in the treatment of adrenocortical carcinoma (ACC), and although it has been used for several decades, its exact mechanism of action, remain to be fully elucidated. Some authors reported that mitotane affected in vitro the multidrug resistance gene mdr-1/P-glycoprotein. MRP1, belonging a multidrug resistance protein family, exerts a chemo-resistance activity in many type of cancer leading to the failure...